3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
fludarabine
52
Cyclophosphamide
50
venetoclax
47
Azacitidine
44
fludarabine phosphate
41
Whole-Body Irradiation
33
Specimen Handling
31
Mycophenolic Acid
30
Tacrolimus
28
Melphalan
28
Busulfan
27
Cytarabine
25
Stem Cell Transplantation
23
Decitabine
23
Biopsy
22
Granulocyte Colony-Stimulating Factor
19
Sirolimus
16
Peripheral Blood Stem Cell Transplantation
16
Filgrastim
16
Thiotepa
15
decitabine and cedazuridine drug combination
14
Injections
13
Cyclosporine
13
ruxolitinib
9
Methotrexate
9
Mesna
9
Hematopoietic Stem Cell Transplantation
9
X-Rays
8
Idarubicin
8
Daunorubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Sunitinib
×
1 year
×
Clear all
No trials found.